Novel management of critically induced polyneuropathy in intensive care patients: A case report of two patients

There has been tremendous growth in patients requiring critical care with severe infections. During a prolonged stay in the intensive care unit (ICU), patients develop critical illness polyneuropathy (CIP). The early identification of neurological involvement requires special attention during ICU ca...

Full description

Saved in:
Bibliographic Details
Published inJournal of anaesthesiology, clinical pharmacology Vol. 37; no. 2; pp. 290 - 292
Main Authors Ahuja, Vanita, Selvam, Selwin, Chander, Anjuman, Sawal, Nishit
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer India Pvt. Ltd 01.04.2021
Medknow Publications and Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
Care and treatment
Case Report
critical illness polyneuropathy
Hospital patients
Imipenem
intensive care unit
Metronidazole
Polyneuropathies
pyridostigmine
Tazobactam
Testosterone
Vincristine
intensive care unit
testosterone
pyridostigmine
Critical illness polyneuropathy
Online AccessGet full text

Cover

More Information
Summary:There has been tremendous growth in patients requiring critical care with severe infections. During a prolonged stay in the intensive care unit (ICU), patients develop critical illness polyneuropathy (CIP). The early identification of neurological involvement requires special attention during ICU care. We describe two cases who developed complete motor weakness after a prolonged stay in ICU. Patients were successfully managed with pyridostigmine and testosterone hormonal therapy initially and later with pyridostigmine only. The present case series highlights the need for early recognition, assessment, and novel management of CIP in ICU patients. However, the role of nutrition, physiotherapy, and supportive care is equally essential for the successful outcome in these patients.
ISSN:0970-9185
2231-2730
DOI:10.4103/joacp.JOACP_427_19